The agreement includes development and commercialization of gepirone ER as well as development opportunities for follow-on products. Subject to approval, gepirone ER will be the first-in-class 5HT1a agonist
The trial will involve up to 3,000 participants at five sites throughout South Africa and is expected to continue for four years. “This trial will answer several major
The drug has been approved in 80mg, 120mg and 160mg doses. Sotalol Hydrochloride Tablets are the generic version of Berlex’s Betapace tablets, which had US sales of approximately
The company will be developing compounds that target inflammation in the blood vessel wall as an innovative approach to the treatment of heart disease. The combined company's lead
The researchers reported that endocannabinoids, naturally occurring chemicals found in the brain that are similar to the active compounds in marijuana, helped trigger a dramatic improvement in mice
Based upon preliminary analyses, the safety profile is consistent with the currently marketed Xibrom formulation. The Xibrom once-daily formulation contains both a higher concentration of the active ingredient,
Ostabolin-C has demonstrated strong bone building activity in preclinical studies. Ostabolin-C met the primary objective of this 4 month study by demonstrating a highly statistically significant, dose responsive
As part of the agreement, DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income. Since December 2002,
The phase Ia clinical trial is designed to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. The study will be conducted in Europe. Preclinical research conducted on
GlaxoSmithKline claims the drug helps people lose 50% more weight than diet alone. The drug is intended for people 18 and older to use along with a reduced-calorie,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.